Neeraja Dasari, MD
Radiation Oncology · Decatur, TXNPI 1306884853
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,266 and has fallen 96.3% since, to $47 in 2025.
Across 112 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$230
- Lilly USA, LLC$156
- Amgen$140
- Novartis$138
- Merck$113
- Incyte Corporation$89
- plus $1K from 36 others
What the payments were for
- Food & beverage$1,95599%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $230 |
| Lilly USA, LLC | 9 | $156 |
| Amgen | 7 | $140 |
| Novartis | 8 | $138 |
| Merck | 6 | $113 |
| Incyte Corporation | 6 | $89 |
| Lexicon Pharmaceuticals, Inc. | 6 | $85 |
| Johnson & Johnson | 4 | $65 |
| Bayer | 4 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $60 |
| Bristol Myers Squibb | 3 | $55 |
| Verastem, Inc. | 3 | $52 |
| Regeneron Healthcare Solutions, Inc. | 2 | $50 |
| Tactile Systems Technology Inc | 3 | $42 |
| Eisai Inc. | 2 | $39 |
| Siemens Medical Solutions USA, Inc. | 2 | $36 |
| Sanofi | 2 | $35 |
| GSK | 2 | $35 |
| Astellas Pharma US Inc | 2 | $32 |
| Corium, LLC | 1 | $28 |
| Boston Scientific | 1 | $28 |
| Taiho Oncology, Inc. | 2 | $27 |
| Fortovia Therapeutics, Inc. | 2 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Seagen Inc. | 1 | $24 |
| Sobi, Inc | 1 | $23 |
| Dendreon Pharmaceuticals LLC | 1 | $22 |
| Novocure Inc. | 1 | $21 |
| Puma Biotechnology, Inc. | 1 | $20 |
| Heron Therapeutics, Inc. | 1 | $20 |
| Pfizer | 1 | $20 |
| Exelixis Inc. | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Mirati Therapeutics, Inc. | 1 | $17 |
| Pinnacle Biologics, Inc | 1 | $16 |
| AbbVie | 1 | $16 |
| Mylan Institutional Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Dova Pharmaceuticals | 1 | $13 |
| Tesaro, Inc. | 1 | $13 |
| Acrotech Biopharma Inc. | 1 | $12 |
How this compares
$1,967 in reported general payments places this provider in the 70th percentile of 418 radiation oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other radiation oncology in Decatur
- James WelshHouston$421K
- Stephen ChunHouston$344K
- Jim HsiangCorpus Christi$258K
- Chad TangHouston$183K
- Phuoc TranHouston$177K
- Hak ChoyDallas$119K
- Steven LinHouston$105K
- Benjamin SchrankHouston$100K
- Robert TimmermanDallas$77K
- Abhilasha PatelHouston$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.